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O
n this journey from nanoparticle
(NP) synthesis and characterization
to animal models, a number of
common themes emerge: how do we eval-
uate the potential for translation of new
materials? What should be our stan-
dards for NP characterization and for their
biological properties? How do we im-
prove the robustness and reproducibility
of our devices, measurements, and conclu-
sions? These questions will need to be
addressed to progress more eﬀectively
and safely toward biomedical applications.
Translation toward the clinic is already
happening, yet great challenges remain
before these approaches will make a sig-
niﬁcant diﬀerence to a large number of
patients.
The diversity of nanomaterials available
provides a formidable toolbox, but one
that is now so vast that we can only use it
eﬀectively if we have a clear understanding
of what each tool is and of what it can do. In
that context, standards and careful charac-
terization of these nanomaterials and their
surfaces is essential. Sometimes the tools
exist but are not used systematically, while
in other cases, new methods are required.
Nanoparticles also need to be character-
ized at diﬀerent points in their life cycle
as they are generally dynamic systems. A
question as basic (and fundamentally
important) as “do NPs go through biological
membrane barriers?” remains open and
requires further experimentation. There is
also a large knowledge gap regarding the
interactions of NPs at the whole animal
level that reﬂect their performance in can-
cer imaging, sensing, and therapy; their
metabolization and expulsion from the
body; their eﬀects on the immune system;
and the choices of animal models that are
eﬀective at predicting outcomes in humans.
Better materials characterization, better
experimental design, new measurement
techniques that allow for real-time molecu-
lar-level information at the NPbiological
interface, advanced in vitro testing (three-
dimensional cocultures) and computer
models, systematic sharing of data, more
eﬀective interdisciplinary collaborations,
publication of both positive and negative
The societal impact of
nanotechnologies, if properly
deployed, is enormous.
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ABSTRACT
Nanoparticles have the potential to contribute to new modalities in molecular imaging and sensing as well as in therapeutic interventions. In this Nano Focus
article, we identify some of the current challenges and knowledge gaps that need to be confronted to accelerate the developments of various applications.
Using speciﬁc examples, we journey from the characterization of these complex hybrid nanomaterials; continue with surface design and (bio)physicochemical
properties, their fate in biological media and cells, and their potential for cancer treatment; and ﬁnally reﬂect on the role of animal models to predict their
behavior in humans.
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results, and critical discussion of
published evidence are just a few
suggested steps toward a more ro-
bust scientiﬁc enterprise.
Nonetheless, the societal impact
of nanotechnologies, if properly de-
ployed, is enormous. In addition to
NPs for human health, NPs are com-
ponents of next-generation technol-
ogies for cleaner water, cleaner air,
and cleaner energy. A thorough un-
derstanding of the issues raised on
the biomedical application side will
also help other NP industries pro-
duce their technologies in a safe
and sustainable manner.
CORESHELL NANOPARTICLES:
THE CORE MATTERS
Researchers are generating an im-
mense collection of new nanomater-
ials, which diﬀer by the composi-
tion of their (inorganic) cores and
(organic) ligand shells. While many
are proposed as potential candi-
dates for biomedical applications,
only a few are, or will be, really
translated. In this ﬁrst section, we
use iron oxide NPs as a case study to
illustrate the need for detailed char-
acterization of the inorganic core.
These NPs combine magnetic prop-
erties with low toxicity and biode-
gradability. Translation has started
with current applications in sensing,
imaging and therapy.
Fundamental changes in the
magnetic structure of macroscopic
magnetically orderedmaterials occur
when the physical size is reduced.
A bulk ferromagnet spontaneously
subdivides into a multidomain struc-
ture to reduce the magnetostatic
energy associated with a large stray
ﬁeld. A critical size exists;which is
both material and shape dependent,
although typically on the order of
100 nm;at which only a single do-
main structure can be supported.
Further reduction in size leads to
the superparamagnetic state. In this
state, thermal agitation results in the
instability of the magnetic moment,
which ﬂips between easy axes on a
time scale on the order of nano-
seconds.1 Although the spin struc-
ture of the superparamagnetic and
single domains is identical, the two
states diﬀer in the nature and the
dynamics of their magnetic re-
sponse. The magnetic behavior of
the superparamagnetic state is anal-
ogous to the Langevin model of
atomic paramagnetism. However,
instead of dealing with the mag-
netic moment of a single atom, in
the superparamagnetic state of a
magnetic nanocrystal, there are on
the order of 105 atoms that are mag-
netically coupled by the exchange
interaction.2 The reader is referred to
the reviewsbyPankhurt3,4 for anover-
view of the underlying physics that
governs these changes in magnetic
behavior, with Cullity5 recommended
for a more detailed discussion.
Bioapplications of magnetic NPs
have been explored for several
decades6,7 and now extend to mag-
netic separation, delivery (actuation),
hyperthermia treatment, and con-
trast enhancement agents for mag-
netic resonance imaging (MRI). In
this broad interdisciplinary ﬁeld,
the terms “single domain” and
“superparamagnetic” particles are
often used interchangeably; the
subtle diﬀerences in the dynamics
of themagnetic responsemean that
it is important to make the distinc-
tion between these two diﬀerent
regimes.
Iron oxide can exist in diﬀerent
chemical compositions such as
magnetite (Fe3O4) or maghemite
(γ-Fe2O3) or, most likely, a non-
stoichiometric combination of the
two. Understanding of the long-
term biotransformation, and conse-
quently toxicity, requires a precise
knowledge of the injected NP.8 As
Fe2þ ions play a critical role in bio-
chemical processes that generate
free radicals, in vivo applications of
superparamagnetic NPs require ac-
curate and precise quantiﬁcation
of the amount of Fe2þ. Fe3þ ions
are signiﬁcantly less reactive and
are the form used for iron storage
within the body.
Although the magnetic response
is primarily governed by the object
size, it is also aﬀected by the physical
shape, the crystallographic structure,
and microstructural quality. The
contributions to the total energy of
the ferromagnetic system are not
isotropic, with anisotropic contribu-
tions associated with both the crys-
tal structure (magnetocrystalline
anisotropy) and the shape (mag-
netostatics) of the particle. While it
is necessary to perform thorough
characterization of a rangeof proper-
ties of magnetic NPs, such character-
izations should also be done under
conditions that mimic the physical
environment of the intended appli-
cation. Though this is by no means
trivial, it provides a sound basis for
comparison of materials, interpreta-
tion of performances, as well as clues
for the rational design of the next
generation of particles. Key techni-
ques to analyze magnetic cores and
the in vitro/in vivo fate are described
brieﬂy here.
Structural and Chemical Characteriza-
tion. Structural characterization can
be achieved using a combination of
X-ray diffraction (XRD) and electron
microscopy;including both stan-
dard and high-resolution transmis-
sion electron microscopy (TEM, HR-
TEM).
Diﬀraction techniques may be
preferred over imaging techniques
such as electron microscopy (EM)
since they are limited by the small
amount of material that can be
imaged. The full width at half-
maximum (FWHM) of diﬀraction
peaks can be ﬁtted using the Scher-
rer equation and provides informa-
tion on microstrain as well as the NP
size distribution. For iron oxides, the
interpretation of the diﬀraction peak
positions is complicated by the fact
that the lattice parameters of mag-
netite and maghemite are extre-
mely similar (amagnetite = 8.396 Å;
amaghemite = 8.346 Å). Structural
studies should always be comple-
mented with spectroscopy that
probes the chemical environment
such as Mössbauer, electron energy
loss spectroscopy (EELS), or X-ray
photoelectron spectroscopy (XPS).
It is only with such spectroscopies
that the Fe2þ/Fe3þ ratio can be
quantiﬁed. However, XPS probes
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the chemical environment at the
surface, while Mössbauer probes
themean ironoxidationdegreewith-
in the whole volume of the NP. On
the other hand, EELS is more qualita-
tive and can only be performed on
oneparticle at a time. Therefore, pure
magnetite, pure maghemite, core
shell magnetitemaghemite, or in-
termediate composition can be dis-
tinguishedbyusing a combination of
these techniques.
Electron microscopy does, how-
ever, provide invaluable insights
into the range of shapes present
and, when combined with electron
diﬀraction, oﬀers a powerful way
with which to probe the evolution
of crystallographic quality. In some
recent work,9,10 the transformation
of iron oxide NPs has been observed
by following the crystallographic
structure evolution of superpara-
magnetic maghemite into an amor-
phous, poorly magnetic iron species
over the course of three months
in vivo. This example nicely illustrates
the beneﬁt of complete characteriza-
tion since it enables demonstration
of the association of a loss of mag-
netic properties with the bio-
transformation of the material into
poorly magnetic species (rather than
a disappearance of the material).
Magnetic Characterization. By defi-
nition, the superparamagnetic state
is characterized by two features: the
lack of remanence and the tempera-
ture dependence of magnetization
curves (magnetization curves nor-
malized by temperature super-
impose, i.e., a plot of M/T vs H/T).2
Static magnetization measurements
can be used to confirm the superpara-
magnetic state and can be performed
using vibrating samplemagnetometry
(VSM) or superparamagnetic quan-
tum interference device (SQUID)
magnetometry.
By ensuring that all magnetome-
try measurements are performed on
noninteracting systems, analysis of
room-temperature magnetization
curves can clearly and unambiguously
provide a wealth of information con-
cerning the particle size distribution of
the starting material.1114 The initial
susceptibility is sensitive to larger par-
ticles,while theapproach to saturation
is governed by smaller particles. The
value of magnetization at saturation
(MSB) is signiﬁcantly diﬀerent for bulk
magnetite and maghemite (at 297 K,
MSB[magnetite]∼ 480 emu/cm3while
MSB[maghemite] ∼ 300 emu/cm3). In
addition, the large surface-to-volume
ratio of NPs results in saturation mag-
netization of the particles, MSP, that is
typically lower than that of the bulk
material (due to the higher number of
surface defects). This saturation mag-
netization can be further reduced by
poor crystal structure. Thus, to avoid
misinterpreting a strongly magnetic
maghemite sample with a weakly
magnetic magnetite sample, magne-
tization measurements should always
be performed in conjunction with
structural and chemical characteriza-
tion so that the correct phase of iron
oxide is identiﬁed.
The articles by Chen et al.12 and
El-Hilo13 are two excellent examples
that discuss how to extract the
magnetic size distributions of super-
paramagnetic NPs from magnetiza-
tion curves, which can be achieved
by ﬁtting experimentally measured
curves using the simple Langevin
expression modiﬁed by a log-
normal distribution. Such articles
highlight the need to move beyond
working in terms of a single particle
size and magnetic response, when
instead there is always a distribution
of sizes and shapes. Small changes
in the shape cannot be neglected
when dealing with magnetic spe-
cies. Changes in shape can cause
magnetostatic interactions, which
may aﬀect the colloidal stability;
those may be exacerbated during
their intended applications, as brieﬂy
discussed here.
Any application that requires
magnetic NPs to be internalized
within cells should also characterize
the magnetization measurements
after uptake in order to determine
the eﬀect of intracellular conﬁne-
ment on the magnetic response.
The mechanism of uptake of NPs
by cells is further discussed below,
but it is worth noting here that
particles typically end up seques-
tered in large concentrations within
intracellular vesicles. Close conﬁne-
ment can cause dipoledipole
interactions,15,16 and indeed, some
groups have reported that MRI re-
laxivities of superparamagnetic iron
oxide NPs are often signiﬁcantly
reduced upon internalization by
cells.17,18
Understanding the nature of
magnetization reversal dynamics is
important for magnetic hyperther-
mia applications. When subjected to
alternating current (AC) magnetic
ﬁelds, magnetic NPs cause heating
of the local area due to losses during
magnetization reversal. There are
three diﬀerent mechanisms by which
theparticlesdissipateheat;hysteretic
losses, relaxation (Néel or Brownian),
and viscous (stirring) heating.1921
The physical basis of the heating of
superparamagnetic particles by AC
magnetic ﬁelds has been reviewed
by Rosensweig.22 Brieﬂy, for small
ﬁeld amplitudes, and assumingmini-
mal interactions between the consti-
tuent superparamagnetic particles,
the response to an AC ﬁeld can be
described in terms of its complex
susceptibility. This results in the gen-
eration of heat,22 which can be inter-
preted physically as meaning that if
the magnetization lags the applied
ﬁeld there is a positive conversion of
magnetic energy into internal en-
ergy. The dominant heat loss me-
chanism is determined by the shape
of themagnetization curve, although
these vary in diﬀerent manners on
the amplitude and frequency of
the AC magnetic ﬁeld. Nonetheless,
they are all strongly dependent on
the mean and width of the size
distribution, particle shape, and
crystallinity.19,23 These properties
can be further aﬀected by both
temperature and viscosity of the
physiological conditions.
Unfortunately, most publications
on the development of magnetic
NPs for bioapplications do not re-
port such extensive structural, chem-
ical, and magnetic characterization.
Instead these approaches are often
restricted to investigators primarily
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interested in nanophysics. Such
physical properties are, however, of
direct use to interpret and to under-
stand how the biological environ-
ment aﬀects and modiﬁes the NPs'
magnetic properties. Consequently,
the current literature is based on a
range of materials of various mag-
netic qualities that have been irregu-
larly characterized,whichmakes ﬁnal
observed properties diﬃcult to inter-
pret and to compare.
COMPLEXITY AND BIOCOM-
PATIBILITY OF NANOPARTICLE
SURFACES
As-made colloidal NPs bear ad-
sorbed ions, ligands, or other mol-
ecules on their surfaces. Generally
speaking, these “native species” on
the NP surface are not the ﬁnal
desired surface coatings. As-made
NPs may be too hydrophobic for
biological applications, or toxicity
concerns of the ligands may arise.
Therefore, many workers in the ﬁeld
engage in surface bioconjugation
of NPs, usually with the goals of
making nanomaterials that (i) are
biocompatible and (ii) would bind
to a particular biological target in or
on a living cell. The most common
chemical linkages between inorganic
NP surfaces and their designer mo-
lecular coats are shown in Figure 1.
Even for a monolayer of identical
molecules on a nanoparticle surface,
variations in surface coverage or
ligand orientation (e.g., lying down or
standing up on the surface) can occur.
The situation becomes even more
complex when mixtures of surface
ligands are coordinated to the NP sur-
face: do the ligands self-assemble into
domains, reminiscent of the lipid raft
hypothesis for cell membranes? Or are
the ligands randomly distributed on
the surface (Figure 2)? Simulation tools
are valuable guides to the engineering
of patchy nanoparticles.2426 Experi-
mental evidence of “patchiness” relies
on either direct molecular-scale ima-
ging, which is diﬃcult to perform on
nanoscale curved surfaces and is sub-
ject to possible artifacts, or on less
direct methods such as mass
spectrometry.2736
One grand challenge in the ﬁeld,
then, is a reliable means of measur-
ing the spatial location of molecules
on nanoscale curved surfaces that
provides chemical information as to
what the molecules actually are.
The importance of molecular dis-
play on nanoscale curved surfaces
becomes apparent when the size of
a typical NP (5200 nm) is com-
pared to that of a small molecule
(1 nm), a typical protein (10 nm), and
a cell (1000100 000 nm). Receptor
clustering is a phenomenon inwhich
proteins or other molecules cluster
together on the surface of a cell an
event that is correlated with intracel-
lular signaling. The size of the average
NP is beautifully suited to anchor onto
a cluster of such molecules and per-
haps even to multiple diﬀerent clus-
ters at once. In other words, even
though the “lock and key” idea of
chemical binding is long past its
prime, it is tempting to imagine that
multiple molecular keys on a NP sur-
face might open multiple cellular
locks in a coordinated way;if the
spatial locations were well-matched.
Even if the presence of a patchy
designer coat on a NP surface is not
needed for a particular application, NP
bioconjugation experiments frequently
proceed with multiple ligands, one
or more for targeting and one or
more for biocompatibility.
The selection of targeting ligands
is, for the most part, driven by exist-
ing biological recognition partners
(antibody/antigen; aptamer/small
molecule; receptor/ligand, cyclic RGD/
integrin, etc.). While a good idea in
principle and in vitro, in practice,
the ability to reach their engineered
target in vivo is questionable, and
may rely more on the enhanced
permeability and retention eﬀect
than surface chemistry (see below).
Another challenge in the ﬁeld,
then, is to measure the percent
yield of designer-coated NPs bind-
ing to their target and understand
themechanisms bywhich this event
fails.
To improve NP biocompatibility,
the most popular coligand is poly-
(ethylene) glycol (PEG; Figure 3).
Although PEG is often considered
to be the current best antibiofouling
surface ligand, carboxy- and sulfo-
betaines have been explored as pos-
sible alternatives (Figure 3).3742
Both PEG and the betaine ligands
are overall neutral in aqueous solu-
tion and very soluble in water; PEG is
known to be well-hydrated. Thus,
surfaces coated with PEG, or be-
taines, resist adventitious protein
adsorption because (i) there are no
charges to make favorable electro-
static contacts with proteins, and (ii)
Figure 1. Schematic of (left) a noblemetal nanoparticle (NP)with thiol anddisulﬁde
surface coatings and (right) a metal oxide NP with carboxylate and phosphonate
coatings. R represents a functional group or recognition unit. The left cartoon
implies metalsulfur bonding; the right implies metal cationanion bonding.
One grand challenge in
the ﬁeld is a reliable
means of measuring the
spatial location of
molecules on nanoscale
curved surfaces that
provides chemical
information as to
what the molecules
actually are.
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the hydration shell eﬀectively looks
like water to the proteins, and so
there is little driving force for pro-
teinsurface binding. As a result of
these ideas, PEG especially is con-
sidered “biocompatible”when really
what is meant is “resistant to protein
(or cellular) adsorption”. The degree
of resistivity to protein adsorption is
by no means 100%; early studies
showed reduction in protein ad-
sorption by a factor of 4 or so.41
Recently, questions about PEG's
biocompatibility have been raised.
Although PEG is Generally Regarded
as Safe (GRAS) by the U.S. Food and
Drug Administration, and its use as a
drug modiﬁer is approved in some
commercial products, PEG does
have limitations in its postuptake
chemistry38,39 and also diﬀerent de-
grees of organ accumulation as a
function ofmolecular weight.38 Poly-
(ethylene) glycol properties such as
molecular weight and surface
density control when bound to a
NP do inﬂuence NP stability.39,43
There are increasing reports of
PEGylated objects inducing comple-
ment activation, which is part of the
immune cascade;4448 these reports
underscore the need to have a di-
versity of options when it comes to
“biocompatible surfaces”. Understand-
ing and predicting these chemical
processes at the NP surface, and
extending the molecular level to
the cellular or organismal level, is a
key challenge for the ﬁeld.
UTILIZING NANOCRYSTALS IN
BIOMEDICINE:PARTICLESURFACE
CHEMISTRY AND BIOLOGICAL
EFFECTS
Nanoparticle High Surface Energy.
Nanocrystals, especially those in
the smallest size range (below
30 nm), may be rather unstable
and short-lived. Energy is required
to form NPs, either from the bulk or
from molecular precursors, and to
create a solidliquid/air interface.
The resulting NPs are reactive and
tend to either grow or dissolve
(Figure 4). Interfacial energy can also
be released via aggregation and
interaction with proteins, both of
which are of special relevance in
the nanobiotechnology context.
Nanoparticle Aggregation. Although
the stability of NPs and conjugates
at physiological conditions has been
the subject of intensive studies,4951
the loss of colloidal stability is often
underestimated. This problem is
particularly acute at high concentra-
tions of NPs, which are required to
reach therapeutic doses and for
in vivo studies. Since the volume
that one can inject is limited, not
more than ∼200 μL in mice, for
example, concentration needs to
be high to achieve reasonable
doses. Thus, in many cases, the loss
of colloidal stability is behind the
lack of (or unexpected) biological
effects.52,53 Indeed, surface modifi-
cation of NPs is always required for
biomedical applications because
the environment where the NPs
are produced and the physiological
environment where they should
perform are different and usually
incompatible. This is especially im-
portant in environments where so-
lutions with high ionic strength,
such as biological fluids (e.g., blood,
lymph, and urine), induce compres-
sion and screening of the ionic dou-
ble layer that forms around the NPs
in aqueous solutions, allowing them
to get close together, leading to
aggregation if a steric stabilizing
agent is not present.54
Since small size is a key func-
tional feature of these systems, any
Figure 2. Schematic of randomly arrangedmolecular adsorbates on a nanoparticle (NP) surface (left), compared to adsorbates
arranged in patches (right) on a NP surface.
Figure 3. Chemical structures of (a) poly(ethylene) glycol (PEG), (b) sulfobetaine,
and (c) carboxybetaine.
Surface modiﬁcation of
nanoparticles is always
required for biomedical
applications because
the environment where
the nanoparticles are
produced and the
physiological
environment where
they should perform are
diﬀerent and usually
incompatible.
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induced aggregationwill dramatically
aﬀect cellular and molecular re-
sponses. Additionally, NPs may ag-
gregate to sizes large enough to
induce frustrated phagocytosis re-
sulting in chronic inﬂammation
and consequent risk of promoting
cancer or neurodegeneration.55
Nanoparticle Protein Corona. Usual-
ly, proteins present in biological
media play the role of stabilizing
agent by forming a protective pro-
tein corona on the surface of theNPs
as soon as they come into contact
with serum, thus preventing aggre-
gation.50,56 However, under certain
conditions, this is not enough to
prevent aggregation, for example,
when working with high concentra-
tion of NPs in cell culture media or
animal models (>1012 NC/mL).57
Nanoparticles, in general, strongly
interact with macromolecules, a spe-
cial case being interactions with pro-
teins, their equivalent-sized biological
counterparts. The interaction of NPs
with proteins and other molecules
may alter the metabolism of biologi-
calmolecules, and the conjugates can
be detected by the immune system,
evoking a pro-inﬂammatory response.
The protein corona also inﬂuences
the interactions of NPs with the cell
membrane.58 Adsorption of proteins
also modiﬁes the surface charge50 of
the NP and therefore determines
how it interacts with biological pro-
cesses.59,60 In addition, once the pro-
tein corona is formed, opsonins and
proteins of the complementary sys-
tem may be able to recognize pro-
teins adsorbed on the surface of the
NP which would trigger an immune
response.61,62 Additionally, confor-
mational changes due to adsorption
of proteins on the particle surfacemay
cause lack of recognitionby theorgan-
isms or may cause autoimmunity.63
Adsorbed proteins may also in-
ﬂuence signaling, when extracellu-
lar proteins internalize into cells
carried by NPs or when binding of
NPs to cells changes structure or
association patterns of self-proteins.64
The interaction of proteins with NPs
maymodify protein activity and struc-
ture and interfere with their natural
fate. Therefore, the eﬀect of diﬀerent
corona compositions on intracellular
detection mechanisms needs to be
investigated. In some cases, the ad-
sorbed proteins can induce signaling
by exposing new epitopes upon
binding to the NP surface,65 thus
interacting with speciﬁc receptors
on the cell membrane, such as re-
ceptors involved in lipoprotein traf-
ﬁcking, complement receptors, and
pattern recognition receptors as the
toll-like receptor family.66 Addition-
ally, modiﬁcation of the protein
structure or environment due to
conjugation may have other impor-
tant eﬀects, as induction of expo-
sure of hydrophobic residues and
consequent aggregation and pro-
tein denaturalization, or modiﬁca-
tion in how proteins are recognized,
employed, and processed.
Diﬀerent modes of surface func-
tionalization can also modify the
way proteins absorb. This deter-
mines the fate of the NPs inside
the body, varying from innocuous
and eliminated through the urine
in minutes67,68 to provoking strong
andaggressive immune (anaphylactic)
response.69,70
It is important to note that the
immune system is especially sensi-
tive to natural nano-objects, such as
misfolded or non-self-proteins, pro-
tein aggregates, and protein pat-
terns (e.g., virus surfaces). This is
why the humoral and cellular im-
munedefense response toengineered
Figure 4. Nanoparticle (NP) cycle. To generate NPs through bottom-up or top-down fabrication requires energy that the
formed NPs tend to dissipate either by aggregation or by chemical transformation.
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NPs is also critical: NPs have dimen-
sions similar to those of proteins,
protein aggregates, and viruses
and are recognized by immune cells,
so they are subject to eﬃcient pro-
tective strategies that prevent their
uncontrolled access into the body.
Nanoparticles could induce immu-
nogenic epitope generation, that is,
cause deformation of protein ter-
tiary structure (promoted by the
interaction with the curved NP
surface) that can induce protein ag-
gregation or make self-proteins
immunogenic, thereby inducing
autoimmune reactions, as antigens
absorbed onto NPs could become
allergenic. Additionally, it is known
that epitope concentration, repeti-
tion, and patterning induced by as-
sociation of proteins or peptides to
NPs can be observed to trigger an
immune response.66 Given the
above considerations, it is clear that
the interaction between NPs and
other biological molecules may cause
a modiﬁcation of both, with conse-
quences for human health that are
not yet easy to predict. In this context,
previous NP albuminization to satu-
rate the NP surface with proteins
seems a simple and eﬀective strat-
egy to biocompatibilize and to avoid
NPprotein interaction; PEGylation
is also used, as discussed above.
Extensive investigations into the
formation of the protein corona
have shown that hydrophobic NPs
get rapidly coated by the fraction of
the serum proteins dedicated to
detecting foreign objects, as lipo-
polysaccharide (LPS) or misfolded
protein and protein aggregates, ba-
sically immunoglobulins and apolipo-
proteins. Additionally, hydrophilic sur-
face NPs get progressively coated by
serum albumin;which counts for
50% of all proteins in the serum;in
a process that may take minutes to
hours and results in a permanent
protein corona enveloping the NPs.
Surfactant molecules present on the
particle surface may eﬀectively inter-
fere with the absorption process,
succeeding in completely avoiding
protein absorption in some cases, as
with PEGylation.71
MECHANISM OF CELL ENTRY
AND EXIT
In a previous Nano Focus article,72
authors stated that “surface-modiﬁed
NPs can directly reach the cytosols
of living cells”. Indeed, this impres-
sion seems to be relatively widely
shared in the nanoscience and chem-
istry literature, with many authors
making the case for the preparation
of new materials on the basis of the
special capacity of NPs to cross cell
membranes. Vincent Rotello, how-
ever, speaking at the E-MRS sympo-
sium Q (spring 2013, Strasbourg),
noted that “amateurs worry about
howNPs get into cells; experts worry
about how they get out of the en-
dosome.” A critical look at the litera-
ture shows that reaching the cytosol
remains a major challenge and that
we are far from understanding, let
alone controlling, the interactions of
NPs with cells or even with model
membranes. Before focusing on the
recent literature on NP/membrane
interactions, it is perhaps useful to
reﬂect on the history of a related
ﬁeld;cell-penetrating peptides
(CPPs);and on some basic biology
and thermodynamics arguments.
The CPP ﬁeld has now entered its
third decade. Initial reports on CPPs
concluded that there was rapid
passive temperature-independent
transport of the CPPs and of their
cargoes through the cell membrane
with low toxicity. These highly excit-
ing properties contributed to the
massive growth of this ﬁeld of re-
search, but it was later found that
ﬁxation prior to microscopy obser-
vation induced a redistribution of
the molecules. In live cells, punctate
patterns characteristic of endocyto-
sis were observed. For several years,
endocytosis became the generally
accepted mode of transport for
CPPs, details of molecular pathways
were elucidated, and the direct in-
volvement of various cell surface
proteins and glycosaminoglycans
were demonstrated. In recent years,
experiments on model membranes
(e.g., giant unilamellar vesicles and
cells) have indicated that while a
range of endocytotic mechanisms
are indeed the main contributors
in live cells, in some cases, passive
diﬀusion through the membrane
does occur depending on lipid com-
position, cargoes, and membrane
potential.73,74 In spiteof over 20years
of research and more than 20000
publications, many basic questions
remain to be clariﬁed in the ﬁeld of
CPPs, and what is emerging is a
highly complex set of scenarios re-
sulting in increased uptake through
various internalization pathways
working in parallel that depend on
cell state and peptide sequence;
CPPs are not a magical route to the
cytosol.73,74
The self-assembly of small mol-
ecules into amembrane that separates
a living entity from its environment is
probably one of the earliest events
in the history of life. The plasma
membrane of eukaryotic cells tightly
controls what does and what does
not enter the interior of cells. Polar
molecules such as ions, peptides,
proteins, oligosaccharides, etc. do
not cross the membrane by diﬀu-
sion: transport is either facilitated by
pore/pump proteins or relies on the
endocytotic processes. In response,
viruses and bacteria have evolved
advanced molecular machineries to
gain access to the interior of cells
through speciﬁc interactions with
the host. Viruses have similar sizes
to NPs, yet no virus relies on simple
A critical look at the
literature shows that
reaching the cytosol
remains a major
challenge and that we
are far from
understanding, let alone
controlling, the
interactions of NPs with
cells or even with model
membranes.
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passive diﬀusion through the mem-
brane to gain access to the cytosol.
The reason is probably simply that
the energy barrier for the passive
diﬀusion of a polar particle of several
nanometers through the cell mem-
brane is much higher than the ther-
mal energy.
Recent literature onNPs and cells/
membranes can be classiﬁed in
three categories: (1) experimental
studies with living cells, (2) theore-
tical studies (necessarily of model
systems), and (3) experimental stud-
ies on model membrane systems.
The ﬁrst category has been critically
reviewed recently by Iversen et al.,
who caution against several experi-
mental and interpretation pitfalls
and make recommendations for fu-
ture studies.75 We certainly second
their concluding remark that “The
complexity, the combination of ad-
vanced chemistry and cell biology,
makes it important that future re-
search on NPs is performed as a
close collaboration between scien-
tists with diﬀerent backgrounds.
This is important to prevent mis-
leading/wrong interpretations and
thus aid in bringing NPs faster into
clinical use.” In addition to interdis-
ciplinary collaborations, more open
and robust discussion of published
evidence (taking inspiration from
the history of the CPPs ﬁeld) is re-
quired. One example of reported
passive diﬀusion of NPs through cell
membranes is the case of the “stri-
py” NPs;76 however, both the struc-
ture and the intracellular localization
have been questioned.27,29,36 Two
recent studies on lipid NPs for the
delivery of siRNA further conﬁrm
that reaching the cytosol remains a
signiﬁcant challenge.77,78 Both stud-
ies show that internalization occurs
via endocytosis and escape to the
cytosol is a rare event. Gilleron et al.
used gold NPs and with extensive
electron microscopy analysis de-
monstrated that only a minor frac-
tion (12%) of siRNAs were released
from endosomes.77,79
The second category (i.e., theore-
tical studies) has been expanding
rapidly in the past few years but is
unfortunately not yet matched by
a growth in the third category of
carefully controlled experiments on
model membranes. Among theore-
tical articles, we note that Li et al.
oﬀer support for favored transport
of NPs with striated ligand patterns
across membranes compared with
random conﬁguration of ligands.80
On the contrary, Gkeka et al. show
that a ligand conﬁguration that
avoids hydrophobic patches as
much as possible minimizes the en-
ergy trap.81 It is worth noting that, in
both cases, there is an energy trap of
over 10 kBT for these particles that
have a signiﬁcant proportion of hy-
drophobic ligands with favorable
interactions with the interior of the
membrane. Incorporation of hydro-
phobic NPs into lipid membranes is
relativelywell understood,82 and the
use of NPs/colloids as surface active
materials to stabilize emulsions is
a mature industrial ﬁeld.83 Clear
experimental evidence of passive
transport of NPs across model mem-
branes, however, remains elusive.
INORGANIC NANOPARTICLES
FOR CANCER: HYPERTHERMIA
AND BIMODAL THERAPY
The use of heat to kill tumors has
been known since the ancient Greek
times and is called hyperthermia.84
It consists of an increase in tempera-
ture just above the physiological
temperature to induce cytotoxic ef-
fects on cancer cells because, in
tumor mass, tumor cells show a dis-
organized and compact vascular
structure, and heat dissipation is
hindered in comparison to healthy
tissues.85 To increase the tempera-
ture, a variety of clinical methods
have been employed, including the
application of microwaves and ultra-
sound. However, suchmethods have
limited spatial and temporal control,
and therefore, burns to surrounding
healthy tissues are often inevitable.
Magnetic hyperthermia, whereby
magnetic NPs are used for the con-
trolled generation of heat to kill
cancer cells, while limiting damage
to the surrounding tissue, was ﬁrst
developed in 1957 (Figure 5).6 Heat
generation by means of plasmonic
gold or silver NPs under near-infra-
red (NIR) laser irradiation has also
been previously reported.8688 The
traditional understanding is that a
sustained change in temperature
above a threshold of ∼42 C results
in destruction of malignant tissue,
although recent work suggests that
toxicity may be achieved without
bulk temperature change, possibly
through damage to intracellular or-
ganelles leading to lysosomal con-
tent release.89,90
The heating ability of magnetic
NPs is deﬁned as the speciﬁc absorp-
tion rate (SAR) (sometimes called
speciﬁc loss power, SLP), which, in
turn, is determined by the particle
material, size, and shape. The heat
generated by NPs can only be
understood when the magnetic,
physical, and hydrodynamic size dis-
tributions are accurately known (see
refs 19, 23, and 95 and discussion on
core characterization in the previous
section). Gonzalo Vallejo-Fernandez
et al. argue that SAR can only be
reliably measured when the parti-
cles are embedded within a solid
matrix, thus simulating the NP loca-
lization at the tumor.23 It is also
important to remark that the ﬁeld
and frequency have to be kept be-
low a certain threshold in order to be
clinically applied.95,96 This has not
always been the case for many
proof-of-concept studies.94,97
Evenwithhigh SARparticles, in vivo
implementation is constrained by the
need to achieve high local concentra-
tion of nanomaterials at the tumor
site. Superparamagnetic NPs that
can circulate long enough into the
blood to lead to the required tumor
accumulation and that present the
optimal therapeutic dose for the
heat treatment while avoiding sys-
temic toxicity are still missing. It is
unclear whether further improve-
ments to the surface chemistry and
colloidal stability of the NPs com-
bined with active targeting will pro-
vide a widely applicable strategy
since therapies based on systemic
injections are fundamentally limited
by diﬀerent physiological barriers: (i)
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the extravasation ﬁrst from the vas-
cular system to the tumor, (ii) the
distribution among the tumor re-
gions, and ﬁnally (iii) the targeting
toward diﬀerent subsets of tumor
cell populations (i.e., cancer stem
cells (CSCs) versus non-CSCs).
Nonetheless, magnetic NPs have
been approved for medical devices,
and MagForce (Berlin, Germany) has
translated magnetic hyperthermia
for the treatment of glioblastoma
multiforme. Their treatment does
not rely on systemic injection. In-
stead, it consists of injecting 15 nm
aminosilane-coated SPIONs directly
into the solid tumor with a specially
designed surface to ensure that
NPs remain at the site of injection,
thus allowing for multiple magnetic
exposure.98,99
Since chemo- and radiotherapy
are the most common treatments
for cancer, NPs that combine the
functions of heat mediator foci with
the capability to deliver and to
release drugs may broaden the
scope of biomedical applications.
Attempts have beenmade to exploit
the heat produced by the NP as a
trigger mechanism enabling spatial
and temporal control of drug re-
lease. Mechanisms include break-
ing thermosensitive linkers,9193
the opening of “polymer gates”
from silica-functionalized mag-
netic NPs,100 or the disruption of
molecular assemblies.101
In a couple of recent examples,
dehybridization of oligonucleotides
was used as a tool to engineer a
temperature-sensitive gate for drug
release.93,94,102 Ruiz-Ernàndez et al.
encapsulated a model drug into sili-
ca nanopores blocked by DNA hy-
bridized with iron oxide NPs bearing
the complementary DNA strand. In
this study, a macroscopic increase in
temperature, above 4245 C, re-
sulted in melting and subsequent
release of the drug, thus combining
hyperthermia with drug release.
More recently, drug release has
been achieved without the need to
reach a macroscopic temperature
change. This eﬀect relies on the
quite signiﬁcantheatproﬁlegenerated
Figure 5. Schematic illustrating magnetically induced hyperthermia and drug release. (A) Magnetic nanoparticles (NPs) at a
deﬁned concentration, when exposed to an alternatingmagnetic ﬁeld, can induce a temperature rise as a consequence of their
magnetic vibrations. (B) Heat produced locally by themagneticNP canbeused to release drugs associated to theNP surface via
thermosensitive linkers.9193 In this case, drug release could occur even if the global temperature of the system does not
change macroscopically; a local temperature increase is responsible for such release.91,92,94
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at the NP surface, upon alternating
magnetic ﬁeld (AMF) exposure, within
a contour of only a few nano-
meters.91,92,94 As such local changes
are essentially independent of NP con-
centration, some of the limitations of
systemic injections noted above may
be relaxed. Achieving the very high
drug loading required to achieve a
local therapeutic dose might then be-
come the next challenge.
New opportunities might come
from hollow iron oxide NPs, which
can be both magnetic hyperthermia
agents and nanocontainers for drug
molecules.103105 The thin shell
structure can either be broken via
sonication104 or similar treatments
such as by using focused ultrasound
treatment106 or electroshock wave
lithotripsy, which is typically applied
for the treatment of renal stones. In
the case of hollow nanostructures
containing platinum, such as iron
platinum NPs or FePt@Fe2O3 yolk
shell NPs, the degradation of the
fragile hollow shell under acidic pH
in cells also allows the gradual re-
lease of cytotoxic ions, the Pt2þ ions,
thus generating cytotoxicity eﬀects
toward the cells that have interna-
lized the nanostructures.107,108
To introduce new therapeutic
agents, the net beneﬁcial eﬀects
have to be signiﬁcant in comparison
with the present treatment applied.
To reach this point, a careful inves-
tigation of potential new nanome-
dicines must include in vitro char-
acterization of their eﬀects on living
cells, proof of principle in vivo (in a
suitablemodel, see discussion in the
next section), as well as studies of
eﬃcacy, biodistribution, in vivo ac-
cumulation, and degradation to elu-
cidate the fate of the materials, their
potential long-term toxicity, and
their body elimination at the dose
needed for the treatment. This ap-
proach has already been applied in
the case of iron oxide NPs.109 To
move ahead, a continuous feedback
is needed between design, charac-
terization, and evaluation to opti-
mize the therapeutic performance
while minimizing the side eﬀects.
PREDICTING NANOPARTICLE
BEHAVIOR IN HUMANS: HOW
GOOD ARE THE CURRENT
CELLULARANDANIMALMODELS?
Profound understanding of how
NPs that are made from diﬀerent
materials interact with various or-
gans and cells is important for
optimizing novel sensing, imaging,
anddrug-delivery systems. Toachieve
this goal, theuseof relevant biological
models is needed. At the cellular
level, it is understandable that cells
will vary in their interaction with a
particular NP since cells from diﬀer-
ent organs and origin have diﬀer-
ent biological functions, membrane
compositions, and structures. Thus,
both the interaction at the mem-
brane level and the intracellular fate
of the NP (traﬃcking, signaling, and
disposition of the NP and its cargo)
areﬀerent in diﬀerent cell types and
within diﬀerent organs.
As an example, we discuss here
the well-studied lipid-based nano-
particles (LNPs) to show how these
materials can interact with subsets
of cells fromthe immunesystem.110,111
Lipid-based NPs (e.g., liposomes, li-
poplexes, micelles, etc.) are NPs self-
assembled from a variety of natu-
rally occurring and synthetic lipids
creating large panels of structures
with unique architectures and prop-
erties. However, despite the advan-
tages of increased stability, facilitated
delivery, and cargo protection, fol-
lowing systemic administration, LNPs
may trigger the innate immune arm
of the immune system, especially the
complement cascade and macro-
phage/dendritic cells clearance me-
chanisms (Figure 6).112,113
Like other circulating particles,
LNPs such as liposomes are often
Figure 6. Iteraction of diﬀerent lipid-based nanoparticles (LNPs) with subsets of
leukocytes can suppress or activate the immune response. The ﬁrst line of defense by
the innate immune arm includes diﬀerent pattern recognition receptors such as
membrane-bound toll-like receptors (TLRs), cytoplasmic NOD-like receptors (NLRs),
and scavenger receptors on innate immune cells such as monocytes, macrophages,
anddendritic cells. The second lineof defense includes the adaptive immunearmwith
several important T helper subsets such as TH1, TH2, TH17, Tregs, TH9, and TH22 cells.
Each subset of leukocytes can interact diﬀerentlywith diﬀerent types of nanoparticles
made from diﬀerent materials and with diﬀerent sizes, geometries, and surface
charges. Adapted with permission from ref 114. Copyright 2012 Elsevier B.V.
Profound
understanding of how
nanoparticles that are
made from diﬀerent
materials interact with
various organs and cells
is important for
optimizing novel
sensing, imaging, and
drug-delivery systems.
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ﬁrst taken up by phagocytic cells
(such as blood monocytes and spe-
cialized macrophages of the liver
[Kupﬀer cells, also known as stellate
macrophages], spleen, and bone
marrow).115 Theremight be undesir-
able interactions between the lipo-
somes and the immune system,
such as immunostimulation or im-
munosuppression. Liposomes have
been well-documented as agonists
of toll-like receptors (TLRs)116,117
and can also be internalized into
macrophages by scavenger recep-
tors, but there is a lack of immuno-
logical knowledge about the inter-
action of liposomes and other LNPs
with nucleotide-binding oligomeri-
zation domain (NOD)-like receptors
(NLRs) and speciﬁcally with the
inﬂammasome. Liposomes can also
activate, complement, or induce an
“educational” event with the adap-
tive immune system. Interactions of
LNPs with TH and B-lymphocytes are
less well characterized and have
tremendous potential for exploring
new avenues in the adaptive im-
mune system.112,118,119
The inadvertent recognition of
liposomes as foreign entities by
leukocytes may result in a multilevel
immune response against the lipo-
somes and eventually lead to toxi-
city in the host and/or lack of
therapeutic beneﬁt.115,120 A harmful
activation of the complement cas-
cade may occur in some types of
particles. This event may lead to hy-
persensitivity reactions and anaphyl-
axis.121 Szebeni et al. showed that
intravenous injection of LNPs could
cause acute hypersensitivity reac-
tions (HSRs) in up to 45% of patients,
with hemodynamic, respiratory, and
cutaneous manifestations. The phe-
nomenon can be explained with
activation of the complement sys-
tem on the surface of lipid particles,
leading to anaphylatoxin (C5a and
C3a) liberationandsubsequent release
reactions ofmast cells, basophiles, and
possibly other inﬂammatory cells in
the blood.122
Lipid-based nanoparticles deco-
rated with poly(ethylene) glycol
(PEG) and entrapping doxorubicin
(Doxil) also activate the comple-
ment system. The reported fre-
quency of HSRs to Doxil is up to
25% of all the treated patients. Un-
like an IgE-mediated (type I) allergy,
these reactions occur mostly at the
ﬁrst exposure to the formulation
without prior sensitization.123 An
additional example is a harmful ac-
tivation of the complement system
at tumor sites, which may stimulate
tumor-associated immune cells and
promote their conversion into a tumor-
supportive phenotype, thereby stimu-
lating cancer progression.113,121,124
Not only are NP interactions with
diﬀerent cell types still not well-
documented but there is also an
even larger knowledge gap at the
whole animal level. Adequate ani-
mal models to study the biological
properties of NPs with speciﬁc or-
gans in a whole animal are neces-
sary. In that context, NPs that are
also imaging contrast agents are
advantageous. The majority of anti-
tumor studies, for example, are con-
ducted in immunodeﬁcient mice
(e.g., severe combined immunodeﬁ-
ciency, SCID, Rag-deﬁcient mice) to
allow investigations on human sam-
ples; however, these animals possess
a compromised adaptive immune
system that reduces the eﬀect of
antigen-presenting cell-mediated
NP clearance. Nanoparticle phar-
macokinetic studies should be con-
ducted in immune-competent ani-
mals, both on those that are healthy
and others that are diseased. The
rapidly induced animal tumors that
potentiate the enhanced permeabil-
ity and retention (EPR) eﬀect may
not be representative of all human
tumors; therefore, caution must be
observed in predicting the transla-
tional capability of certain NPs eval-
uated in these models.
Since it was ﬁrst reported by
Matsumura and Maeda in 1986,125
the EPR eﬀect has been utilized by
diﬀerentmacromolecules and, among
them, nanotechnology-based plat-
forms to deliver drugs to solid tu-
mors. The defective architecture of
tumor neovasculature allows the
extravasation of macromolecules
over 40 kDa to the tumor interstitial
space, while the ineﬀective lympha-
tic drainage allows them to remain
there (Figure 7).
However, although several EPR-
based nanomedicines are in clinical
use (e.g., Doxil, Abraxane, and
Marqibo), the potential therapeutic
eﬃcacy of EPR-based nanomedi-
cines has been hampered by the
heterogeneity of the EPR eﬀect
within and between diﬀerent tu-
mors and by limited experimental
data from patients on the eﬀective-
ness of this mechanism as related to
drug accumulation in the tumor site
that is translated into real eﬃcacy.
The heterogeneity in EPR may be a
major contributing factor to the lim-
ited success of nanomedicines with
reductions in toxicity accompanied
by the limited gains in overall survi-
val as compared with traditional
chemotherapy and small-molecule
anticancer agents.126 Several meth-
ods have been proposed to aug-
ment the EPR eﬀect, including (1)
increasing blood pressure during
infusion of a nanomedicine using
angiotensin-II and (2) using vascular
mediators such as nitroglycerin,
angiotensin-converting enzyme in-
hibitor, or nitric oxide.127
One of the fundamental limita-
tions in evaluating EPR is the lack
of knowledge regarding which pre-
clinical tumor models recapitulate
patients with solid tumors. Several
main factors aﬀect the delivery of
nanomedicines to tumors in precli-
nical models, such as the rate of
tumor growth, vasculature, tumor
environment, functional mononu-
clear phagocyte system (MPS), etc.,
and appear to vary based on the
tumor model (e.g., subcutaneous
xenograft, orthotopic xenograft, ge-
netically engineered mouse model)
used. The majority of antitumor
studies are conducted in immune-
compromised mice to enable inves-
tigations on human xenografts and
recently also on a patient's own tumor,
known as tumorgraft. Nevertheless,
these animals possess a compromised
MPS,which couldhave adistinct eﬀect
on nanomedicine pharmacokinetic
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studies and thus pharmacokinetic
studies should be conducted in im-
mune-competent animals in order to
reﬂect more accurately on human
cancers.128 Furthermore, commonly
used subcutaneous tumor xeno-
grafts possess vasculature found in
very high EPR tumors independent
of tumor type and thus could pro-
vide a false impression regarding
the beneﬁt of nanomedicines in
most tumor settings when relying
on the EPR eﬀect.126
Future studies will need to evalu-
ate these factors systemically in pre-
clinical models and in patients with
various solid tumors and match the
most suitable preclinical model to
each human tumor accordingly.
Moreover, further investigations are
required to understand how to
assess drugs relying on the EPR ef-
fect for eﬃcacy in preclinical tumor
models and to understand how they
reﬂect the heterogeneity seen in
human disease. A promising venue
for better understanding and pre-
dictability of EPR function in humans
comes from the use of clinical ima-
ging studies, which may help the
development ofmore eﬀective nano-
medicines. In one such study,
pharmacokinetics and biodistribu-
tion of 111In-labeled PEGylated lipo-
somes were evaluated in patients
with diﬀerent advanced tumors.
Although positive tumor images
were obtained in 15 of 17 studies,
the levels of tumor liposome uptake
varied signiﬁcantly both between
and within tumor types, emphasizing
the need for further comprehensive
studies of EPR-based nanomedicines
in patients.129
At the same time, more selective
delivery strategies are being devel-
oped,130133 utilizing active cellular
targeting upon reaching the tumor
vicinity (Figure 7). It is likely that
these strategies will govern the new
therapeuticmodality for bothdiagnos-
tics (molecular imaging), therapeutics
(targeted, cell-speciﬁc delivery), and
perhaps also theranostics.134
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